StreetInsider.com News Articles

Form 8-K Arbutus Biopharma Corp For: May 26

Wed, 27 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260527/26557633.html

Form 8-K Arbutus Biopharma Corp For: May 26

Wed, 27 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260527/26557633.html

Form SCHEDULE 13G/A Arbutus Biopharma Corp Filed by: Two Seas Capital LP

Fri, 15 May 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20260515/26508052.html

Form SCHEDULE 13G/A Arbutus Biopharma Corp Filed by: Two Seas Capital LP

Fri, 15 May 2026 17:34:00 -0400

si-local-file:///var/storage/secattach/20260515/26508052.html

Arbutus Biopharma (ABUS) Tops Q1 EPS by 91c

Wed, 13 May 2026 07:47:39 -0400

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of $0.87, $0.91 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $179.23 million versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

Form 10-Q Arbutus Biopharma Corp For: Mar 31

Wed, 13 May 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260513/26481773.html

Form 10-Q Arbutus Biopharma Corp For: Mar 31

Wed, 13 May 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260513/26481773.html

Form 8-K Arbutus Biopharma Corp For: May 13

Wed, 13 May 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26481766.html

Form 8-K Arbutus Biopharma Corp For: May 13

Wed, 13 May 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26481766.html

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 07:30:00 -0400

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026

FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review

WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update.

LNP